Cellectis (NASDAQ:CLLS) Cut to “Hold” at StockNews.com

StockNews.com downgraded shares of Cellectis (NASDAQ:CLLS) from a buy rating to a hold rating in a research report report published on Wednesday.

Cellectis Price Performance

Shares of NASDAQ CLLS opened at $1.30 on Wednesday. The stock’s 50-day simple moving average is $1.45 and its two-hundred day simple moving average is $1.78. Cellectis has a twelve month low of $1.14 and a twelve month high of $3.38. The firm has a market capitalization of $72.26 million, a P/E ratio of -1.00 and a beta of 3.27. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48.

Cellectis (NASDAQ:CLLS) last issued its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.22). Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. The company had revenue of $33.22 million during the quarter, compared to the consensus estimate of $5.90 million. As a group, equities analysts anticipate that Cellectis will post -0.46 EPS for the current fiscal year.

Hedge Funds Weigh In On Cellectis

Institutional investors have recently modified their holdings of the company. Millennium Management LLC bought a new stake in Cellectis in the 4th quarter worth approximately $962,000. B Group Inc. purchased a new position in shares of Cellectis during the fourth quarter worth approximately $5,547,000. Finally, Wells Fargo & Company MN lifted its holdings in shares of Cellectis by 103.4% in the 4th quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 12,500 shares during the last quarter. 63.90% of the stock is currently owned by institutional investors.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.